Advocacy intelligence hub — real-time data for patient organizations
Vanderbilt-Ingram Cancer Center — PHASE1
Centre Georges Francois Leclerc — NA
Zhujiang Hospital
Qunxing Li,MD — PHASE3
AbbVie — PHASE1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — PHASE2
Zhujiang Hospital
Shanghai Zhongshan Hospital — PHASE2
Centre Leon Berard — NA
VLP Therapeutics — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
LYMPHOSEEK
(technetium Tc 99m tilmanocept)Orphan drugstandardCardinal Health 414, LLC
12.1 Mechanism of Action Lymphoseek (technetium Tc 99m tilmanocept) is a radioactive diagnostic agent. It accumulates in lymphatic tissue and selectiv...
Browse all Squamous cell carcinoma of the oral cavity news →
Douglas Adkins, MD
Washington University School of Medicine
📍 ANN ARBOR, MI
Julie E Bauman, M.D. MPH
NRG Oncology
📍 WASHINGTON, DC
Marcelo Bonomi, MD, MD
Wake Forest University Health Sciences
📍 COLUMBUS, OH
Lillian Siu, MD
Princess Margaret Hospital, Canada
Christopher M Lee, MD
Cancer Care Northwest
Stephen Y Lai
NRG Oncology
View all Squamous cell carcinoma of the oral cavity specialists →